letter Open AccessTop 1% cited
COVID-19: combining antiviral and anti-inflammatory treatments
The Lancet Infectious Diseases · 2020 · Vol. 20(4) · pp. 400–402
Justin Stebbing✉(Imperial College London)Anne M. Phelan(BenevolentAI (United Kingdom))Ivan Griffin(BenevolentAI (United Kingdom))Catherine Tucker(BenevolentAI (United Kingdom))Olly Oechsle(BenevolentAI (United Kingdom))D. Casey Smith(BenevolentAI (United Kingdom))Peter J. Richardson(BenevolentAI (United Kingdom))
SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesComputational Drug Discovery MethodsMedicineScopusCoronavirus disease 2019 (COVID-19)CoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyMEDLINEInternal medicineDiseaseBiology
MeSH terms
BetacoronavirusCOVID-19SARS-CoV-2COVID-19 Drug TreatmentAnti-Inflammatory AgentsAntiviral AgentsAzetidinesPneumonia, ViralPurinesPyrazolesSulfonamidesCoronavirus InfectionsPandemics
Citations
1,150
FWCI
27.76
field-weighted impact
References
7
Percentile
100%
vs. same field & year
Citations per year
Cited by
Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts
Journal of Leukocyte Biology · 2020 · 779 citations
Can atmospheric pollution be considered a co-factor in extremely high level of SARS-CoV-2 lethality in Northern Italy?
Environmental Pollution · 2020 · 924 citations
References
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
The Lancet · 2020 · 51,571 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.